A Locke Lord trial team led by Keith Parr (Chicago) represented Lupin Pharmaceuticals Inc. and Lupin Ltd. in a patent infringement case. At trial, the team argued for the U.S. District Court for the Southern District of Indiana to rule that one of Acrux DDS Pty Ltd’s patents licensed to Eli Lilly & Co. covering Axiron, a testosterone drug, is invalid, and that Lupin’s applicator would not infringe a second patent that Acrux had also licensed to Lilly. On appeal, the U. S. Court of Appeals for the Federal Circuit affirmed the judgment in its entirety. Lupin received final FDA approval for its testosterone product in late October 2017, before the Federal Circuit’s decision, clearing the way for launch of its product. The Locke Lord trial team included David Abramowitz, Carolyn Blessing and Nina Vachhani (all of Chicago). Hugh Balsam (Chicago) assisted with the appeal.
Posted on November 30, 2017